Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001999371-26-025220

Q3 2026 · 10-Q
Revenue$20.16M+38.1% vs Q3 2025+31.5% vs Q2 2026
Net Income$3.67MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted$0.05N/M vs Q3 2025no prior Q2 2026 on file
Gross Profit$7,928,000+128.2%
Operating Income$4,036,000N/M
Operating Cash Flowderived$6,719,000N/M
Margins · derived
Gross margin39.3%+15.5 pt vs Q3 2025
Operating margin20.0%+24.7 pt vs Q3 2025
Net margin18.2%+25.2 pt vs Q3 2025

What the release said

Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2026.

Solésence reported third quarter 2026 revenue of $20.2 million, compared to $14.6 million for the same period in 2025, and a gross margin of 39.3%, compared to 23.8%.23

The CEO said the company completed the primary investment and implementation phase of its first pillar, operational excellence, in the third quarter.4

Third quarter 2026 revenue
$20.2 million Compared to $14.6 million for the same period in 20252
Third quarter 2026 net income
$3.7 million Compared to a net loss of $1.0 million for the same period in 20255
Third quarter 2026 gross profit
$7.9 million Compared to $3.5 million for the same period in 20256
Third quarter 2026 gross margin
39.3% Compared to 23.8% for the same period in 20253
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$20.16M$14.60M$16.87M$7.96M
Net Income$3.67M-$1.02M$2.72M-$1.44M
EPS Diluted$0.05-$0.01$0.04-$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Solesence, Inc. · CIK 883107 · Engraved from SEC EDGAR